SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
AssigneeThe California Institute for Biomedical Research
InventorsTravis YOUNG, Chanhyuk KIM, Peter G. SCHULTZ
Life of this patent
Estimating the term…
Abstract
Disclosed herein are switchable chimeric receptors, switchable chimeric receptor effector cells and chimeric receptor effector cell switches. The switchable chimeric receptor-ECs are generally T cells. The chimeric receptors have non-antibody extracellular domains that recognize a chimeric receptor binding partner on the chimeric receptor-EC switch or target cell. The chimeric receptor-ECs and switches may be used for the treatment of a disease or condition in a subject in need thereof.
Claims159
A chimeric receptor comprising:
- a. a non-antibody extracellular domain that interacts with a chimeric receptor binding partner, wherein the chimeric receptor binding partner is present on a switch that comprises the chimeric receptor binding partner and a targeting moiety;
- a transmembrane domain;
- and
- c. an intracellular signaling domain, wherein the intracellular signaling domain signals to an effector cell on which the chimeric receptor is expressed when the non-antibody extracellular domain interacts with the chimeric receptor binding partner.
A chimeric receptor comprising:
- a. a non-antibody extracellular domain that interacts with a chimeric receptor binding partner;
- a transmembrane domain;
- and
- c. an intracellular signaling domain, wherein the intracellular signaling domain signals to an effector cell on which the chimeric receptor is expressed when the non-antibody extracellular domain interacts with the chimeric receptor binding partner.
The chimeric receptor of any one of the preceding claims, wherein the targeting moiety is selected from a targeting small molecule, a targeting peptide, a targeting protein, a targeting antibody, and a targeting antibody fragment.
A chimeric receptor-effector cell switch comprising:
- a. a chimeric receptor binding partner that interacts with a non-antibody extracellular domain of a chimeric receptor on an effector cell;
- and
- b. a targeting moiety that interacts with a cell surface molecule on a target cell.
A pharmaceutical composition comprising:
- a. a chimeric receptor-effector cell switch comprising:
- i. a chimeric receptor binding partner that interacts with a non-antibody extracellular domain of a chimeric receptor on an effector cell;
- and
- ii. a targeting moiety that interacts with a cell surface molecule on a target cell;
- and
- b. a pharmaceutically acceptable salt, carrier, excipient and/or vehicle.
A kit comprising:
- a. a chimeric receptor-effector cell switch comprising:
- i. a chimeric receptor binding partner that interacts with a non-antibody extracellular domain of a chimeric receptor on an effector cell;
- and
- ii. a targeting moiety that interacts with a cell surface molecule on a target cell;
- and
- b. a chimeric receptor-effector cell comprising a chimeric receptor that binds to the chimeric receptor binding partner of the chimeric receptor-effector cell switch.
A vector comprising a polynucleotide having a sequence that encodes a chimeric receptor, wherein the chimeric receptor comprises a non-antibody extracellular domain.
A method of treating a disease or condition in a subject in need thereof, comprising administering to the subject a chimeric receptor-effector cell switch comprising:
- a. a chimeric receptor binding partner that interacts with a non-antibody extracellular domain of a chimeric receptor on an effector cell;
- and
- b. a targeting moiety that interacts with a cell surface molecule on a target cell.
A method of treating a disease or condition in a subject in need thereof, comprising:
- A. administering to the subject a chimeric receptor-effector cell comprising:
- i. chimeric receptor comprising:
- a. a non-antibody extracellular domain that interacts with a chimeric receptor binding partner, wherein the chimeric receptor binding partner is present on a switch that comprises the chimeric receptor binding partner and a targeting moiety;
- b. a transmembrane domain;
- and
- c. an intracellular signaling domain, wherein the intracellular signaling domain signals to an effector cell on which the chimeric receptor is expressed when the non-antibody extracellular domain interacts with the chimeric receptor binding partner;
- and
- B. administering to the subject a chimeric receptor-effector cell switch comprising:
- i. a chimeric receptor binding partner that interacts with a non-antibody extracellular domain of a chimeric receptor on an effector cell;
- and
- ii. a targeting moiety that interacts with a cell surface molecule on a target cell.
Dependencies are inferred from the claim text.